[{"address1": "350 Oyster Point Boulevard", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 624 3000", "website": "https://www.cytokinetics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 423, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert I. Blum", "age": 60, "title": "CEO, President & Director", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 1326057, "exercisedValue": 9614474, "unexercisedValue": 90413080}, {"maxAge": 1, "name": "Dr. Fady Ibraham Malik FACC, M.D., Ph.D.", "age": 60, "title": "Executive Vice President of Research & Development", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 839665, "exercisedValue": 586170, "unexercisedValue": 40148980}, {"maxAge": 1, "name": "Mr. Andrew M. Callos", "age": 55, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 752838, "exercisedValue": 0, "unexercisedValue": 7529940}, {"maxAge": 1, "name": "Dr. James A. Spudich Ph.D.", "age": 82, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1942, "fiscalYear": 2023, "totalPay": 21938, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sung H. Lee", "age": 54, "title": "Executive VP, Principal Financial & Accounting Officer and CFO", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeff  Lotz", "title": "Vice President of Sales & Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Yang", "title": "Vice President of Corporate Finance and Financial Planning & Analysis", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steven M. Cook J.D.", "age": 65, "title": "Senior Vice President of Global Supply Chain Operations & Technical Operations", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kari K. Loeser J.D.", "title": "VP & Chief Compliance Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John O. Faurescu Esq.", "title": "VP, Associate General Counsel & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 4, "compensationRisk": 6, "shareHolderRightsRisk": 7, "overallRisk": 6, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://phx.corporate-ir.net/phoenix.zhtml?c=142156&p=irol-IRHome", "maxAge": 86400, "priceHint": 2, "previousClose": 46.17, "open": 46.23, "dayLow": 42.73, "dayHigh": 46.23, "regularMarketPreviousClose": 46.17, "regularMarketOpen": 46.23, "regularMarketDayLow": 42.73, "regularMarketDayHigh": 46.23, "beta": 0.783, "forwardPE": -8.265773, "volume": 3486569, "regularMarketVolume": 3486569, "averageVolume": 1267185, "averageVolume10days": 1410390, "averageDailyVolume10Day": 1410390, "bid": 42.65, "ask": 42.86, "bidSize": 200, "askSize": 100, "marketCap": 5046278656, "fiftyTwoWeekLow": 42.73, "fiftyTwoWeekHigh": 81.36, "priceToSalesTrailing12Months": 1567.6542, "fiftyDayAverage": 48.8022, "twoHundredDayAverage": 53.9144, "currency": "USD", "enterpriseValue": 5345251328, "floatShares": 117414728, "sharesOutstanding": 118014000, "sharesShort": 14030843, "sharesShortPriorMonth": 13730415, "sharesShortPreviousMonthDate": 1734048000, "dateShortInterest": 1736899200, "sharesPercentSharesOut": 0.1189, "heldPercentInsiders": 0.0053600003, "heldPercentInstitutions": 1.19389, "shortRatio": 11.45, "shortPercentOfFloat": 0.1814, "impliedSharesOutstanding": 118014000, "bookValue": -0.118, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -576401984, "trailingEps": -5.38, "forwardEps": -5.39, "lastSplitFactor": "1:6", "lastSplitDate": 1372118400, "enterpriseToRevenue": 1660.532, "enterpriseToEbitda": -10.457, "52WeekChange": -0.399922, "SandP52WeekChange": 0.21027291, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "CYTK", "underlyingSymbol": "CYTK", "shortName": "Cytokinetics, Incorporated", "longName": "Cytokinetics, Incorporated", "firstTradeDateEpochUtc": 1083331800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "39e332a5-8990-3a41-9526-4fd099b8f8a6", "messageBoardId": "finmb_27315", "gmtOffSetMilliseconds": -18000000, "currentPrice": 42.76, "targetHighPrice": 120.0, "targetLowPrice": 60.0, "targetMeanPrice": 80.8, "targetMedianPrice": 79.0, "recommendationMean": 1.75, "recommendationKey": "buy", "numberOfAnalystOpinions": 20, "totalCash": 1011692032, "totalCashPerShare": 8.573, "ebitda": -511143008, "totalDebt": 908225984, "quickRatio": 9.215, "currentRatio": 9.276, "totalRevenue": 3219000, "revenuePerShare": 0.03, "returnOnAssets": -0.30128, "grossProfits": -327536000, "freeCashflow": -242420992, "operatingCashflow": -404356992, "revenueGrowth": 0.225, "operatingMargins": -304.10583, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]